Skip to main content
SpringerLink
Log in

Impact of Comorbidity on Treatment Decision Making and Outcomes

  • Chapter
  • First Online:
Cancer and Chronic Conditions

  • 875 Accesses

Abstract

Cancer, like many chronic conditions, is a disease of aging, and more than half of cancer patients in developed countries are 65 years or older. Therefore, many cancer patients have comorbidities, high use of medications, altered body composition, pharmacokinetics, and pharmacodynamics. Therefore, the treatment plans need to be individually tailored to achieve optimal outcomes. This chapter on comorbidity in cancer decision making gives some general principles and then will review some specific comorbidities with their incidence, considerations for decision making and treatment outcome. Scores to assess the risk of toxicity from chemotherapy will also be reviewed. Comorbidity burden is a major influencer of life expectancy and should be integrated in life expectancy estimates. The most assessed comorbidities are renal insufficiency and hepatic diseases. Creatinine clearance should be systematically calculated, and for several types of treatment, the Child-Pugh classification can be used. We also review the treatment of patients with cardiovascular diseases, auto-immune/inflammatory diseases, and diabetes. All risk factors of comorbidity should be comprehensively evaluated before cancer treatment, in order to reduce treatment-related toxicity and improve patient outcomes. Future research should address how to integrate the impact of multiple concomitant comorbidities, and more specifically which subgroups most affect various cancer outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Howlader N NA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/, Apr 2015

  2. Extermann M, Overcash J, Lyman GH et al (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582–1587

    CAS  PubMed  Google Scholar 

  3. Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36:453–471

    Article  CAS  PubMed  Google Scholar 

  4. Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181–200

    Article  CAS  PubMed  Google Scholar 

  5. Anderson G, Kerluke K (1996) Distribution of prescription drug exposures in the elderly: description and implications. J Clin Epidemiol 49:929–935

    Article  CAS  PubMed  Google Scholar 

  6. Kennerfalk A, Ruigomez A, Wallander MA et al (2002) Geriatric drug therapy and healthcare utilization in the United kingdom. Ann Pharmacother 36:797–803

    Article  PubMed  Google Scholar 

  7. Beaufrere B, Morio B (2000) Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 54(Suppl 3):S48–53

    Article  PubMed  Google Scholar 

  8. McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163–184

    Article  CAS  PubMed  Google Scholar 

  9. Balducci L, Extermann M (1997) Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 80:1317–1322

    Article  CAS  PubMed  Google Scholar 

  10. Walter LC, Schonberg MA (2014) Screening mammography in older women: a review. JAMA 311:1336–1347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cho H, Klabunde CN, Yabroff KR et al (2013) Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 159:667–676

    Article  PubMed  Google Scholar 

  12. Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683–1690

    Article  PubMed  Google Scholar 

  13. Kristjansson SR, Rønning B, Hurria A et al (2012) A comparison of two pre-operative frailty measures in older surgical cancer patients. J Geriatr Oncol 3:1–7

    Article  Google Scholar 

  14. Tucci A, Ferrari S, Bottelli C et al (2009) A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115:4547–4553

    Article  PubMed  Google Scholar 

  15. Extermann M, Wedding U (2012) Comorbidity and geriatric assessment for older patients with hematologic malignancies: a review of the evidence. J Geriatr Oncol 3:49–57

    Article  Google Scholar 

  16. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

    Article  CAS  PubMed  Google Scholar 

  17. Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27:387–404

    Article  CAS  PubMed  Google Scholar 

  18. Miller MD, Paradis CF, Houck PR et al (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41:237–248

    Article  CAS  PubMed  Google Scholar 

  19. Miller M, Tower A (1991) A manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). University of Pittsburgh, Pittsburgh, PA

    Google Scholar 

  20. Greenfield S, Blanco DM, Elashoff RM, Ganz PA (1987) Patterns of care related to age of breast cancer patients. JAMA 257:2766–2770

    Article  CAS  PubMed  Google Scholar 

  21. Wallace K, Overcash J, Yoder J, Vranas P, Extermann M (2005) Influence of concomitant medications on toxicity from chemotherapy in elderly patients. Focus on cytochrome P-450 inhibition and protein binding effects. Proc Am Soc Clin Oncol 23:735s

    Google Scholar 

  22. Popa MA, Wallace KJ, Brunello A et al (2014) Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol 5:307–314

    Article  PubMed  PubMed Central  Google Scholar 

  23. Piccirillo JF, Costas I, Claybour P et al (2003) The measurement of comorbidity by Cancer Registries

    Google Scholar 

  24. Yancik R, Wesley MN, Ries LA et al (1998) Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 82:2123–2134

    Article  CAS  PubMed  Google Scholar 

  25. Charlson ME, Sax FL, MacKenzie CR et al (1986) Assessing illness severity: does clinical judgment work? J Chronic Dis 39:439–452

    Article  CAS  PubMed  Google Scholar 

  26. Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376–1384

    Article  CAS  PubMed  Google Scholar 

  27. Foundation NK (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–266

    Google Scholar 

  28. Giannelli SV, Patel KV, Windham BG et al (2007) Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc 55:816–823

    Article  PubMed  PubMed Central  Google Scholar 

  29. Launay-Vacher V, Chatelut E, Lichtman SM et al (2007) Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol Off J Eur Soc Med Oncol/ESMO 18:1314–1321

    Article  CAS  Google Scholar 

  30. Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33–64

    Article  CAS  PubMed  Google Scholar 

  31. Lichtman SM, Wildiers H, Launay-Vacher V et al (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14–34

    Article  PubMed  Google Scholar 

  32. Launay-Vacher V, Chatelut E, Lichtman SM et al (2007) Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18:1314–1321

    Article  CAS  PubMed  Google Scholar 

  33. Chen J, Wang XT, Luo PH, He QJ (2015) Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. Support Care Cancer 23:1043–1048

    Article  PubMed  Google Scholar 

  34. Ichioka D, Miyazaki J, Inoue T et al (2015) Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. Jpn J Clin Oncol 45:867–873

    Article  PubMed  Google Scholar 

  35. Langer CJ, Hirsh V, Ko A et al (2015) Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clin Lung Cancer 16:112–120

    Article  CAS  PubMed  Google Scholar 

  36. Lichtman SM, Cirrincione CT, Hurria A et al. (2016) Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an Ancillary Study of CALGB/CTSU 49907. J Clin Oncol

    Google Scholar 

  37. Lee JJ, Kim J, Sehovic M, Extermann M (2015) The association of comorbidity with toxicities and clinical outcomes in elderly cancer patients treated with chemotherapy using heat maps: preliminary results. SIOG

    Google Scholar 

  38. Edwards BK, Noone AM, Mariotto AB et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290–1314

    Article  PubMed  Google Scholar 

  39. Gundling F, Seidl H, Schmidtler F et al (2011) Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis. Anticancer Res 31:2931–2938

    PubMed  Google Scholar 

  40. Eklund JW, Trifilio S, Mulcahy MF (2005) Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 19:1057–1063; discussion 1063–1064, 1069

    Google Scholar 

  41. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–1161

    Article  CAS  PubMed  Google Scholar 

  42. Refky B, Kotb S, Fady T et al (2015) Impact of liver cirrhosis due to chronic hepatitis C viral infection on the outcome of ovarian cancer: a prospective study. BMC Cancer 15:754

    Article  PubMed  PubMed Central  Google Scholar 

  43. Inghilesi AL, Gallori D, Antonuzzo L et al (2014) Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 20:786–794

    Article  PubMed  PubMed Central  Google Scholar 

  44. Chiu J, Tang YF, Yao TJ et al (2012) The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 118:5293–5301

    Article  CAS  PubMed  Google Scholar 

  45. Landgren O, Pfeiffer RM, Kristinsson SY, Bjorkholm M (2010) Survival patterns in patients with Hodgkin’s lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol 28:5081–5087

    Article  PubMed  PubMed Central  Google Scholar 

  46. Gridley G, McLaughlin JK, Ekbom A et al (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311

    Article  CAS  PubMed  Google Scholar 

  47. Abu-Shakra M, Buskila D, Ehrenfeld M et al (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Loprinzi CL, Duffy J, Ingle JN (1993) Postchemotherapy rheumatism. J Clin Oncol 11:768–770

    CAS  PubMed  Google Scholar 

  49. Warner E, Keshavjee al N, Shupak R, Bellini A (1997) Rheumatic symptoms following adjuvant therapy for breast cancer. Am J Clin Oncol 20:322–326

    Article  CAS  PubMed  Google Scholar 

  50. Morales L, Pans S, Verschueren K et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26:3147–3152

    Article  PubMed  Google Scholar 

  51. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ (1981) Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288–292

    Article  CAS  PubMed  Google Scholar 

  52. Papamichael D, Amft N, Slevin ML, D’Cruz D (1998) 5-Fluorouracil-induced Raynaud’s phenomenon. Eur J Cancer 34:1983

    Article  CAS  Google Scholar 

  53. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U (1999) Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 53:242–254

    Article  CAS  PubMed  Google Scholar 

  54. Ronnblom LE, Alm GV, Oberg K (1991) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30:537–540

    Article  CAS  PubMed  Google Scholar 

  55. Ronnblom LE, Alm GV, Oberg KE (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178–183

    Article  CAS  PubMed  Google Scholar 

  56. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Nishino M, Sholl LM, Hodi FS et al (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373:288–290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Mikuls TR, Endo JO, Puumala SE et al (2006) Prospective study of survival outcomes in Non-Hodgkin’s lymphoma patients with rheumatoid arthritis. J Clin Oncol 24:1597–1602

    Article  PubMed  Google Scholar 

  60. Ogle KS, Swanson GM, Woods N, Azzouz F (2000) Cancer and comorbidity: redefining chronic diseases. Cancer 88:653–663

    Article  CAS  PubMed  Google Scholar 

  61. Hamo CE, Bloom MW (2015) Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy. Clin Med Insights Cardiol 9:47–51

    PubMed  PubMed Central  Google Scholar 

  62. Ades F, Zardavas D, Pinto AC et al (2014) Cardiotoxicity of systemic agents used in breast cancer. Breast 23:317–328

    Article  PubMed  Google Scholar 

  63. Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34:1102–1111

    Article  CAS  PubMed  Google Scholar 

  64. Aapro M, Bernard-Marty C, Brain EG et al (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22:257–267

    Article  CAS  Google Scholar 

  65. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin. Cancer 97(11):2869–2879

    Google Scholar 

  66. Dougoud-Chauvin V, Fradley MG, Chen L, Kim J, Walko CM, Sehovic M, Extermann M (2015) Treatment of diffuse large B-cell lymphoma and preexisting congestive heart failure: a retrospective analysis from Moffitt Cancer Center TCC database. Blood 126 (abstr 3957)

    Google Scholar 

  67. Aapro M, Bernard-Marty C, Brain EG et al (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 22:257–267

    Article  CAS  PubMed  Google Scholar 

  68. Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815

    Article  CAS  PubMed  Google Scholar 

  69. Qin A, Thompson CL, Silverman P (2015) Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. J Cancer Surviv 9:252–259

    Article  PubMed  Google Scholar 

  70. Stewart T, Pavlakis N, Ward M (2010) Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 40:303–307

    Article  CAS  PubMed  Google Scholar 

  71. Dy SM, Sharkey P, Herbert R et al (2006) Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer. Crit Rev Oncol Hematol 59:218–225

    Article  PubMed  Google Scholar 

  72. Gross CP, McAvay GJ, Guo Z, Tinetti ME (2007) The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109:2410–2419

    Article  PubMed  Google Scholar 

  73. Siegelmann-Danieli N, Khandelwal V, Wood GC et al (2006) Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach. Clin Breast Cancer 7:59–66

    Article  PubMed  Google Scholar 

  74. Gosmanov AR, Goorha S, Stelts S et al (2013) Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy. Endocr Pract 19:231–235

    Article  PubMed  Google Scholar 

  75. de la Morena Barrio P, Conesa MA, Gonzalez-Billalabeitia E et al (2015) Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. J Natl Compr Canc Netw 13:417–423

    Google Scholar 

  76. Brunello A, Kapoor R, Extermann M (2011) Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 34:292–296

    Article  CAS  PubMed  Google Scholar 

  77. Meyerhardt JA, Catalano PJ, Haller DG et al (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol Off J Am Soc Clin Oncol 21:433–440

    Article  Google Scholar 

  78. Hwang IC, Park SM, Shin D et al (2015) Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. Asian Pac J Cancer Prev 16:595–600

    Article  PubMed  Google Scholar 

  79. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR (2011) Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clin Oncol 29 (abstr 3618)

    Google Scholar 

  80. Sadeghi N, Abbruzzese JL, Yeung SJ, Hassan M, Li D (2011) Effect of metformin on survival of diabetic patients with pancreatic adenocarcinoma. J Clin Oncol 29 (abstr 4063)

    Google Scholar 

  81. Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Extermann M, Bonetti M, Sledge GW et al (2004) MAX2–a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer 40:1193–1198

    Article  CAS  PubMed  Google Scholar 

  83. Extermann M, Chen H, Cantor AB et al (2002) Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 38:1466–1473

    Article  CAS  PubMed  Google Scholar 

  84. Extermann M, Reich RR, Sehovic M (2015) Chemotoxicity recurrence in older patients: risk factors and effectiveness of preventive strategies-a prospective study. Cancer

    Google Scholar 

  85. Extermann M, Boler I, Reich RR et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118:3377–3386

    Article  PubMed  Google Scholar 

  86. Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol 29:3457–3465

    Article  CAS  Google Scholar 

Further Reading

  1. References 2–4, 14, 29, 61, 73, 84 and 85 provide a good starting point for the reader wanting to deepen further their knowledge.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA

    Jae Jin Lee & Martine Extermann

Authors
  1. Jae Jin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martine Extermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martine Extermann .

Editor information

Editors and Affiliations

  1. Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, South Australia, Australia

    Bogda Koczwara

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Lee, J.J., Extermann, M. (2016). Impact of Comorbidity on Treatment Decision Making and Outcomes. In: Koczwara, B. (eds) Cancer and Chronic Conditions. Springer, Singapore. https://doi.org/10.1007/978-981-10-1844-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1844-2_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1843-5

  • Online ISBN: 978-981-10-1844-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation